Identification

Name
Fenofibrate
Accession Number
DB01039  (APRD00405, DB09545)
Type
Small Molecule
Groups
Approved
Description

Fenofibrate is a prodrug of fenofibric acid, an antilipemic agent which reduces both cholesterol and triglycerides in the blood.

Structure
Thumb
Synonyms
  • 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
  • Fenofibrato
  • Fenofibratum
  • Finofibrate
  • FNF
  • Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
  • Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
  • Procetofen
Active Moieties
NameKindUNIICASInChI Key
Fenofibric acidprodrugBGF9MN2HU142017-89-0MQOBSOSZFYZQOK-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AntaraCapsule130 mg/1OralPhysicians Total Care, Inc.2005-12-272011-06-30Us
AntaraCapsule130 mg/1OralOscient Pharmaceuticals Corporation2008-01-30Not applicableUs
AntaraCapsule90 mg/1OralLupin Pharmaceuticals, Inc.2013-11-01Not applicableUs
AntaraCapsule130 mg/1OralLupin Pharmaceuticals, Inc.2009-09-25Not applicableUs
AntaraCapsule43 mg/1OralOscient Pharmaceuticals Corporation2008-01-30Not applicableUs
AntaraCapsule30 mg/1OralLupin Pharmaceuticals, Inc.2013-11-01Not applicableUs
AntaraCapsule43 mg/1OralLupin Pharmaceuticals, Inc.2009-09-25Not applicableUs
Feno-micro-200Capsule200 mgOralPro Doc Limitee1999-08-27Not applicableCanada
FenofibrateCapsule150 mg/1OralH2 Pharma, Llc2014-05-05Not applicableUs
FenofibrateCapsule50 mg/1OralH2 Pharma, Llc2014-05-05Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-feno-microCapsule200 mgOralApotex Corporation1999-03-29Not applicableCanada
Apo-feno-micro CapsulesCapsule67 mgOralApotex Corporation2001-02-21Not applicableCanada
Apo-feno-superTablet100 mgOralApotex Corporation2006-04-21Not applicableCanada
Apo-feno-superTablet160 mgOralApotex Corporation2006-04-21Not applicableCanada
Apo-feno-superTablet200 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-fenofibrateCapsule100 mgOralApotex Corporation1996-10-02Not applicableCanada
Ava-fenofibrate MicroCapsule200 mgOralAvanstra Inc2011-08-222014-08-21Canada
Dom-fenofibrate MicroCapsule200 mgOralDominion Pharmacal1999-12-16Not applicableCanada
Dom-fenofibrate SupraTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-fenofibrate SupraTablet160 mgOralDominion PharmacalNot applicableNot applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CholibFenofibrate (145 mg) + Simvastatin (40 mg)Tablet, film coatedOralMylan Products Limited2013-08-26Not applicableEu
CholibFenofibrate (145 mg) + Simvastatin (20 mg)Tablet, film coatedOralMylan Products Limited2013-08-26Not applicableEu
CholibFenofibrate (145 mg) + Simvastatin (40 mg)Tablet, film coatedOralMylan Products Limited2013-08-26Not applicableEu
CholibFenofibrate (145 mg) + Simvastatin (40 mg)Tablet, film coatedOralMylan Products Limited2013-08-26Not applicableEu
CholibFenofibrate (145 mg) + Simvastatin (20 mg)Tablet, film coatedOralMylan Products Limited2013-08-26Not applicableEu
CholibFenofibrate (145 mg) + Simvastatin (20 mg)Tablet, film coatedOralMylan Products Limited2013-08-26Not applicableEu
International/Other Brands
Fenogal (SMB Laboratories) / Lipanthyl (Abbott) / Lipantil / Lipidil (lbirn)
Categories
UNII
U202363UOS
CAS number
49562-28-9
Weight
Average: 360.831
Monoisotopic: 360.112836867
Chemical Formula
C20H21ClO4
InChI Key
YMTINGFKWWXKFG-UHFFFAOYSA-N
InChI
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
IUPAC Name
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
SMILES
CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1

Pharmacology

Indication

For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Associated Conditions
Pharmacodynamics

Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.

Mechanism of action

Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.

TargetActionsOrganism
APeroxisome proliferator-activated receptor alpha
agonist
Human
UMetalloproteinase
inhibitor
Human
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
UPeroxisome proliferator-activated receptor deltaNot AvailableHuman
UNuclear receptor subfamily 1 group I member 2
partial agonist
Human
Absorption

Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide

Volume of distribution

In healthy adults, the volume of distribution is 30 L. The volume of distribution is 95 L in individuals with moderate renal impairment and creatinine clearance of 50 to 90 mL/min [Label].

Protein binding

Serum protein binding is reported to be around 99% [Label].

Metabolism
Not Available
Route of elimination

Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.

Half life

20 hours

Clearance
  • 1.2 L/h [Eldery]
Toxicity

LD50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Fenofibrate is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Fenofibrate is combined with (S)-Warfarin.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Fenofibrate.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Fenofibrate.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Fenofibrate.
6-Deoxyerythronolide BThe metabolism of Fenofibrate can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Fenofibrate.
AbacavirFenofibrate may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Fenofibrate.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Fenofibrate.
Food Interactions
  • Increased absorption- take with meals.

References

Synthesis Reference

Jean-Francois Boyer, "Medicine based on fenofibrate, and a method of preparing it." U.S. Patent US4800079, issued January, 1988.

US4800079
General References
  1. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7. [PubMed:15124979]
  2. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61. [PubMed:16310551]
External Links
Human Metabolome Database
HMDB0015173
KEGG Drug
D00565
KEGG Compound
C07586
PubChem Compound
3339
PubChem Substance
46507371
ChemSpider
3222
BindingDB
50085042
ChEBI
5001
ChEMBL
CHEMBL672
Therapeutic Targets Database
DAP000270
PharmGKB
PA449594
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Fenofibrate
ATC Codes
C10BA04 — Simvastatin and fenofibrateC10AB05 — FenofibrateC10BA03 — Pravastatin and fenofibrate
AHFS Codes
  • 24:06.06 — Fribic Acid Derivatives
FDA label
Download (283 KB)
MSDS
Download (19.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers7
1CompletedBasic ScienceHigh Cholesterol1
1CompletedBasic SciencePharmacokinetic Variables1
1CompletedOtherFenofibrate / Glucuronosyltransferase / Human Immunodeficiency Virus (HIV) / Hypertriglyceridemias / Protease Inhibitors1
1CompletedTreatmentAdverse Events / Pharmacokinetic Variables1
1CompletedTreatmentAdverse Events / Pharmacokinetics1
1CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Dyslipidemia (Fredrickson Type Ⅱb)1
1CompletedTreatmentDyslipidemia, Renal Insufficiency1
1CompletedTreatmentDyslipidemias1
1CompletedTreatmentHealthy Volunteers7
1CompletedTreatmentPharmacokinetics1
1WithdrawnTreatmentBMI >30 kg/m21
1, 2CompletedTreatmentDyslipidemias1
1, 2RecruitingTreatmentPrimary Biliary Cholangitis1
1, 2TerminatedTreatmentPrimary Sclerosing Cholangitis (PSC)1
2Active Not RecruitingTreatmentHigh Cholesterol1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2CompletedNot AvailableAlcohol Dependence1
2CompletedDiagnosticHealthy Volunteers1
2CompletedDiagnosticMetabolic Syndromes1
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentChronic Cholestasis1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentDyslipidemias2
2CompletedTreatmentDyslipidemias / Hypertriglyceridemias1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hypertriglyceridemias1
2CompletedTreatmentHyperlipidemias2
2CompletedTreatmentHypertriglyceridemias / Non-alcoholic Fatty Liver Disease (NAFLD1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentInsulin Resistance / Minor burns1
2CompletedTreatmentNon Familial Chylocmicronemia Syndrome (Non-FCS)1
2CompletedTreatmentPatients With Metabolic Syndrome1
2CompletedTreatmentPatients With Type 2 Diabetes1
2RecruitingTreatmentHuntington's Disease (HD)1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH)1
2TerminatedTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Dyslipidemias / Sleep Apnea Syndrome1
2TerminatedTreatmentMetabolic X Syndrome Dyslipidemia1
2WithdrawnTreatmentPrimary Biliary Cholangitis1
2, 3CompletedTreatmentDyslipidemia/Glucose Metabolism Disorder1
2, 3CompletedTreatmentDyslipidemias / Spinal Cord Injuries (SCI)1
2, 3CompletedTreatmentMinor burns1
2, 3RecruitingTreatmentMinor burns1
2, 3TerminatedTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
2, 3WithdrawnTreatmentMinor burns1
3Active Not RecruitingTreatmentSevere Hypertriglyceridemia2
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Pressure (Hypertension) / High Cholesterol / Type 2 Diabetes Mellitus1
3CompletedPreventionRetinopathy, Diabetic1
3CompletedTreatmentCardiovascular Disease (CVD)1
3CompletedTreatmentCombined (Atherogenic) Dyslipidemia / Coronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentCombined Hyperlipidemia1
3CompletedTreatmentCoronary Artery Disease / Coronary Heart Disease (CHD) / Dyslipidemias1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia4
3CompletedTreatmentDyslipidemia/Glucose Metabolism Disorder1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentDyslipidemias / High Cholesterol1
3CompletedTreatmentDyslipidemias / Kidney Diseases1
3CompletedTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
3CompletedTreatmentHyperlipidemias5
3CompletedTreatmentHyperlipoproteinemias1
3CompletedTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentMixed hypercholesterolemia2
3RecruitingTreatmentCoronary Artery Disease1
3RecruitingTreatmentHigh Cholesterol2
3RecruitingTreatmentPrimary Biliary Cholangitis2
3TerminatedDiagnosticCoronary Artery Atherosclerosis1
3TerminatedTreatmentHyperlipoproteinemia Type III1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 1 / Diabetic Nephropathies / Retinal Disorders1
3Unknown StatusTreatmentMixed hypercholesterolemia1
3WithdrawnTreatmentHypertriglyceridemias1
4Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypertriglyceridemias / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentHyperlipidemias / Sexual Dysfunctions1
4CompletedNot AvailableDyslipidemias / Vascular Diseases1
4CompletedNot AvailableHypertriglyceridemias / Insulin Resistance1
4CompletedBasic ScienceDyslipidemias1
4CompletedPreventionCholesterol, HDL1
4CompletedPreventionDyslipidemias / Type 2 Diabetes Mellitus1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / High Cholesterol1
4CompletedTreatmentAtherogenic Dyslipidemia / Obesity Associated Disorder1
4CompletedTreatmentBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Hypertriglyceridemias / Lipid Disorders1
4CompletedTreatmentCardiovascular Disease (CVD) / Dyslipidemias / Hypertriglyceridemias1
4CompletedTreatmentCoronary Heart Disease (CHD) / Hyperlipidemias1
4CompletedTreatmentDyslipidemias2
4CompletedTreatmentFenofibrate/Simvastatin Comparison1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Cholesterol / Hyperlipidemia, Familial Combined1
4CompletedTreatmentHypertriglyceridemias3
4CompletedTreatmentInsulin Resistance / Metabolic Syndromes1
4RecruitingTreatmentRetinopathy, Diabetic1
4TerminatedPreventionDyslipidemias1
4TerminatedTreatmentHypertriglyceridemia in Type 4 Hyperlipidemia / Non Diabetic Subjects With Normoglycemia1
4TerminatedTreatmentSecond or Third Degree Burns1
4Unknown StatusBasic ScienceDiabetes Mellitus (DM) / Retinopathy, Diabetic1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
4Unknown StatusTreatmentMicroalbuminuria1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedBasic ScienceCardiovascular Disease (CVD)1
Not AvailableCompletedBasic ScienceMetabolic Syndromes / Prediabetic State1
Not AvailableCompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD) / Heart Diseases / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias / Hypertriglyceridemias / Insulin Resistance1
Not AvailableCompletedTreatmentCoronary Arteriosclerosis / Genetic Diseases, Inborn / Hypoalphalipoproteinemias1
Not AvailableCompletedTreatmentDiabetes Complications / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentHyperlipidemias1
Not AvailableCompletedTreatmentHypertriglyceridemia With the Metabolic Syndrome1
Not AvailableCompletedTreatmentHypertriglyceridemias / Insulin Resistance1
Not AvailableCompletedTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
Not AvailableCompletedTreatmentMixed hypercholesterolemia / Type 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingTreatmentRadiodermatitis1
Not AvailableTerminatedBasic ScienceDiabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableTerminatedBasic ScienceFatty Liver1
Not AvailableTerminatedBasic ScienceFatty Liver / Insulin Resistance1
Not AvailableTerminatedBasic ScienceHealthy Volunteers1
Not AvailableTerminatedTreatmentMetabolic Syndromes1
Not AvailableTerminatedTreatmentPolycystic Ovaries Syndrome1
Not AvailableUnknown StatusBasic ScienceCardiovascular Disease (CVD)1
Not AvailableUnknown StatusBasic ScienceCytokines / Diabetes Mellitus (DM) / Dyslipidemias / Inflammatory Reaction1
Not AvailableWithdrawnTreatmentTissue Lipid Metabolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Abbott Laboratories Ltd.
  • Amerisource Health Services Corp.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Cardinal Health
  • Catalent Pharma Solutions
  • Dispensing Solutions
  • Ethypharm
  • Fournier Pharma Inc.
  • Galephar Pharmaceutical Research Inc.
  • Gate Pharmaceuticals
  • Global Pharmaceuticals
  • Impax Laboratories Inc.
  • Karalex Pharmaceuticals
  • Kowa Pharmaceuticals America Inc.
  • Laboratories Fournier Sca
  • Lake Erie Medical and Surgical Supply
  • Lupin Pharmaceuticals Inc.
  • Mikart Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Novopharm Ltd.
  • Oscient Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Promex Medical Inc.
  • Ranbaxy Laboratories
  • Reliant Pharmaceuticals
  • Resource Optimization and Innovation LLC
  • Sciele Pharma Inc.
  • Shionogi Pharma Inc.
  • Skyepharma Production Sas
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • United Research Laboratories Inc.
Dosage forms
FormRouteStrength
CapsuleOral130 mg/1
CapsuleOral30 mg/1
CapsuleOral43 mg/1
CapsuleOral90 mg/1
CapsuleOral200 mg
CapsuleOral67 mg
TabletOral100 mg
TabletOral160 mg
TabletOral200 mg
CapsuleOral100 mg
Tablet, film coatedOral
CapsuleOral134 mg/1
CapsuleOral134 1/1
CapsuleOral150 mg/1
CapsuleOral200 mg/1
CapsuleOral200 1/1
CapsuleOral50 mg/1
CapsuleOral67 mg/1
CapsuleOral67 1/1
TabletOral145 mg/301
TabletOral160 mg/301
TabletOral54 mg/1
Tablet, coatedOral145 mg/1
Tablet, coatedOral160 mg/1
Tablet, coatedOral48 mg/1
Tablet, coatedOral54 mg/1
Tablet, film coatedOral145 mg/1
Tablet, film coatedOral160 mg/1
Tablet, film coatedOral48 mg/1
Tablet, film coatedOral54 mg/1
TabletOral120 mg/1
TabletOral40 mg/1
CapsuleOral160 mg
TabletOral48 mg
CapsuleOral100 mg/1
TabletOral145 mg
TabletOral145.0 mg
TabletOral48.0 mg
TabletOral145 mg/1
TabletOral160 mg/1
TabletOral48 mg/1
TabletOral50 mg/1
Prices
Unit descriptionCostUnit
Triglide 160 mg tablet6.39USD tablet
Fenoglide 120 mg tablet5.17USD tablet
Antara 130 mg capsule5.13USD capsule
Tricor 145 mg tablet4.69USD tablet
Lipofen 150 mg capsule3.55USD capsule
Lofibra 200 mg capsule3.25USD capsule
Lofibra 160 mg tablet3.11USD tablet
Fenofibrate Micronized 200 mg capsule2.77USD capsule
Fenofibrate 160 mg2.47USD tablet
Fenofibrate 160 mg tablet2.38USD tablet
Lofibra 134 mg capsule2.03USD capsule
Antara 43 mg capsule1.8USD capsule
Fenofibrate Micronized 134 mg capsule1.79USD capsule
Fenoglide 40 mg tablet1.72USD tablet
Tricor 48 mg tablet1.63USD tablet
Triglide 50 mg tablet1.49USD tablet
Lipidil Supra 160 mg Tablet1.4USD tablet
Lofibra 67 mg capsule1.26USD capsule
Lipidil Micro 200 mg Capsule1.23USD capsule
Lipidil Supra 100 mg Tablet1.22USD tablet
Apo-Feno-Micro 200 mg Capsule1.14USD capsule
Fenofibrate Micro 200 mg Capsule1.14USD capsule
Mylan-Fenofibrate Micro 200 mg Capsule1.14USD capsule
Novo-Fenofibrate Micronized 200 mg Capsule1.14USD capsule
Pms-Fenofibrate Micro 200 mg Capsule1.14USD capsule
Ratio-Fenofibrate Mc 200 mg Capsule1.14USD capsule
Fenofibrate Micronized 67 mg capsule1.0USD capsule
Lofibra 54 mg tablet0.99USD tablet
Fenofibrate 54 mg tablet0.81USD tablet
Apo-Feno-Super 160 mg Tablet0.79USD tablet
Novo-Fenofibrate-S 160 mg Tablet0.79USD tablet
Sandoz Fenofibrate S 160 mg Tablet0.79USD tablet
Apo-Feno-Super 100 mg Tablet0.68USD tablet
Novo-Fenofibrate-S 100 mg Tablet0.68USD tablet
Sandoz Fenofibrate S 100 mg Tablet0.68USD tablet
Apo-Fenofibrate 100 mg Capsule0.64USD capsule
Apo-Feno-Micro 67 mg Capsule0.45USD capsule
Novo-Fenofibrate Micronized 67 mg Capsule0.45USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5145684No1992-09-082011-01-25Us
CA2487054No2008-03-182023-05-23Canada
CA2219475No2002-07-092017-12-11Canada
US8124125No2012-02-282024-10-01Us
US8481078No2013-07-092024-10-01Us
US7658944No2010-02-092024-12-09Us
US9173847No2015-11-032024-10-01Us
US6277405No2001-08-212018-01-09Us
US7037529No2006-05-022018-01-09Us
US6074670No2000-06-132018-01-09Us
US7041319No2006-05-092018-01-09Us
US6652881No2003-11-252018-01-09Us
US6589552No2003-07-082018-01-09Us
US6696084No2004-02-242021-09-11Us
US6375986No2002-04-232020-09-21Us
US7320802No2008-01-222023-02-21Us
US7276249No2007-10-022023-02-21Us
US8026281No2011-09-272025-04-22Us
US9314447No2016-04-192033-05-31Us
US7863331No2011-01-042020-08-08Us
US7101574No2006-09-052020-08-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)80.5 °CPhysProp
water solubility0.25mg/ml at 25 °CNot Available
logP5.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000707 mg/mLALOGPS
logP4.86ALOGPS
logP5.28ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.13 m3·mol-1ChemAxon
Polarizability38.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.987
Blood Brain Barrier+0.9334
Caco-2 permeable+0.648
P-glycoprotein substrateNon-substrate0.5571
P-glycoprotein inhibitor INon-inhibitor0.5995
P-glycoprotein inhibitor IINon-inhibitor0.7632
Renal organic cation transporterNon-inhibitor0.9042
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9147
CYP450 3A4 substrateSubstrate0.6735
CYP450 1A2 substrateInhibitor0.7599
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.7619
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7088
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6373
BiodegradationNot ready biodegradable0.9918
Rat acute toxicity2.2250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9887
hERG inhibition (predictor II)Non-inhibitor0.9083
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-f4e7816cd30c8701cce3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0029000000-60bbd2de375b9b56ec55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0190000000-6e83f7c906eaeb363caf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0019-0930000000-fccf28abf1a426a6949b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-07739caadc1c26a7baaa
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-5045a0039b18e3d7dd9a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-25a145c2138d34aa4b52
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0029000000-a98245ce05ccb6a6707e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0190000000-4e9b3e71fc7960db389e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0019-0930000000-9d3908b5ee8b5f59218d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-1090af5e239a872654d9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-5dcab26837d06f9756f8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-2663fed5f3ba78d3c7a5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-4933bea6ce44715c6172
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01qi-0595000000-d3c4c1cce3b5e1fbb33f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01qi-1594000000-9756f301ee5d44577654
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3920000000-91103d7fd9d1063bae9a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0019-0941000000-27e0cd2c4e952b499a9a

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzophenones
Direct Parent
Benzophenones
Alternative Parents
Diphenylmethanes / Aryl-phenylketones / Phenoxyacetic acid derivatives / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Carboxylic acid esters
show 4 more
Substituents
Benzophenone / Aryl-phenylketone / Diphenylmethane / Phenoxyacetate / Phenoxy compound / Aryl ketone / Phenol ether / Benzoyl / Alkyl aryl ether / Chlorobenzene
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, carboxylic ester, monochlorobenzenes, chlorobenzophenone (CHEBI:5001)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49. [PubMed:10494028]
  2. Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000 May 10;271(2):445-50. [PubMed:10799317]
  3. Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, Wrutniak-Cabello C: New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett. 2000 Sep 29;482(1-2):71-4. [PubMed:11018525]
  4. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001 Jul 13;276(28):25841-7. Epub 2001 May 7. [PubMed:11342537]
  5. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism. 2001 Aug;50(8):963-71. [PubMed:11474486]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. [PubMed:10828060]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
mmp20
Uniprot ID
O43923
Uniprot Name
Matrix metalloproteinase-25
Molecular Weight
20353.66 Da
References
  1. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F: Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension. 2007 May;49(5):1084-94. Epub 2007 Mar 12. [PubMed:17353509]
  2. Lebrasseur NK, Duhaney TA, De Silva DS, Cui L, Ip PC, Joseph L, Sam F: Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension. 2007 Sep;50(3):489-96. Epub 2007 Jul 2. [PubMed:17606858]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. [PubMed:11779144]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. [PubMed:11779144]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Creusot N, Kinani S, Balaguer P, Tapie N, LeMenach K, Maillot-Marechal E, Porcher JM, Budzinski H, Ait-Aissa S: Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples. Anal Bioanal Chem. 2010 Jan;396(2):569-83. doi: 10.1007/s00216-009-3310-y. Epub 2009 Nov 29. [PubMed:20024649]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
There are conflicting data in the literature regarding the severity of inhibition. Some studies suggest mild inhibition and some suggest moderate inhibition.
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Prasad GS, Srisailam K, Sashidhar RB: Metabolic inhibition of meloxicam by specific CYP2C9 inhibitors in Cunninghamella blakesleeana NCIM 687: in silico and in vitro studies. Springerplus. 2016 Feb 24;5:166. doi: 10.1186/s40064-016-1794-4. eCollection 2016. [PubMed:27026863]
  2. Kim KY, Mancano MA: Fenofibrate potentiates warfarin effects. Ann Pharmacother. 2003 Feb;37(2):212-5. doi: 10.1177/106002800303700210. [PubMed:12549950]
  3. Fujino H, Yamada I, Shimada S, Hirano M, Tsunenari Y, Kojima J: Interaction between fibrates and statins--metabolic interactions with gemfibrozil. Drug Metabol Drug Interact. 2003;19(3):161-76. [PubMed:14682608]
  4. Fenofibrate FDA label [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on November 20, 2018 00:50